JP2009541398A - 医薬目的のための新規な多官能性化合物 - Google Patents

医薬目的のための新規な多官能性化合物 Download PDF

Info

Publication number
JP2009541398A
JP2009541398A JP2009517014A JP2009517014A JP2009541398A JP 2009541398 A JP2009541398 A JP 2009541398A JP 2009517014 A JP2009517014 A JP 2009517014A JP 2009517014 A JP2009517014 A JP 2009517014A JP 2009541398 A JP2009541398 A JP 2009541398A
Authority
JP
Japan
Prior art keywords
peptide
binder
effector
linker
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009517014A
Other languages
English (en)
Japanese (ja)
Inventor
アンドレ コルターマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2009541398A publication Critical patent/JP2009541398A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009517014A 2006-06-30 2007-07-02 医薬目的のための新規な多官能性化合物 Pending JP2009541398A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80629806P 2006-06-30 2006-06-30
EP06013641 2006-06-30
EP06013640 2006-06-30
PCT/EP2007/005836 WO2008000517A2 (en) 2006-06-30 2007-07-02 Conjugates for innate immunotherapy of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014095688A Division JP2014166186A (ja) 2006-06-30 2014-05-07 医薬目的のための新規な多官能性化合物

Publications (1)

Publication Number Publication Date
JP2009541398A true JP2009541398A (ja) 2009-11-26

Family

ID=38353353

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009517014A Pending JP2009541398A (ja) 2006-06-30 2007-07-02 医薬目的のための新規な多官能性化合物
JP2014095688A Withdrawn JP2014166186A (ja) 2006-06-30 2014-05-07 医薬目的のための新規な多官能性化合物
JP2016114025A Pending JP2017002039A (ja) 2006-06-30 2016-06-08 医薬目的のための新規な多官能性化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014095688A Withdrawn JP2014166186A (ja) 2006-06-30 2014-05-07 医薬目的のための新規な多官能性化合物
JP2016114025A Pending JP2017002039A (ja) 2006-06-30 2016-06-08 医薬目的のための新規な多官能性化合物

Country Status (5)

Country Link
US (1) US8470963B2 (https=)
EP (3) EP3669894A3 (https=)
JP (3) JP2009541398A (https=)
CN (1) CN101528263B (https=)
WO (1) WO2008000517A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513358A (ja) * 2012-03-22 2015-05-11 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ 金結合性及びｅｇｆｒ受容体親和性を有するペプチド、並びに金ナノ構造に結合したペプチド
JP2019523782A (ja) * 2016-05-24 2019-08-29 シンタプ セラピューティクス ゲーエムベーハー 合成化合物
JP2020523413A (ja) * 2017-06-16 2020-08-06 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5872751B2 (ja) * 2006-02-06 2016-03-01 バーナム インスティテュート フォー メディカル リサーチ 腫瘍および損傷のターゲティングに関する方法および組成物
WO2008121354A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
US20120010153A1 (en) 2009-01-14 2012-01-12 Andre Koltermann Novel tumor-targeting compounds
IN2012DN02345A (https=) 2009-09-16 2015-08-21 Univ Duke
WO2015161094A1 (en) 2014-04-16 2015-10-22 Duke University Electrospun cationic nanofibers and methods of making and using the same
WO2017079537A1 (en) 2015-11-04 2017-05-11 Duke University Polycationic polymers for use in treating and detecting cancer
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
EP3823630A4 (en) 2018-07-19 2022-04-20 The Regents Of The University Of California PEPTIDES FOR THE ACTIVATION OF CELLULAR SIGNALING IN OSTEOPROGENITOR CELLS
CN109055476B (zh) * 2018-08-07 2021-07-09 河南大学 一种生物活性肽p11在治疗甲状腺癌的药物中效果分析方法
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用
CN111474370B (zh) * 2020-04-22 2021-04-06 天津医科大学总医院 检测甲酰肽或甲酰肽受体-1配体含量的方法及应用
WO2022189361A1 (en) * 2021-03-08 2022-09-15 Universiteit Gent Conjugates including multiple saccharidic chains on a linear protein and uses in mammals feed
CN115448980A (zh) * 2021-06-08 2022-12-09 戴德森医疗财团法人嘉义基督教医院 表面链结标靶多肽的类病毒颗粒及其用途
WO2025262329A1 (en) 2024-06-21 2025-12-26 Syntab Therapeutics Gmbh Synthetic molecules comprising tlr2 ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US20030099629A1 (en) * 1999-03-11 2003-05-29 Immunomedics, Inc. Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
CZ391097A3 (cs) 1995-06-07 1998-07-15 Ortho Pharmaceutical Corporation Látky a peptidy vážící se na erythropoietinový receptor
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
DE19853778C1 (de) 1998-11-21 2000-09-21 Basf Ag DNA-Sequenzen kodierend einen Glutamat/Malat-Translokator, Plasmide Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
WO2000031261A2 (en) 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
MXPA02011727A (es) 2000-05-26 2003-10-24 Johnson & Johnson Peptidos neuroprotectores.
IL156942A0 (en) 2001-01-16 2004-02-08 Univ Ramot Compounds, pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1532159A4 (en) * 2002-06-20 2009-10-21 Univ Maryland Biotech Inst MALEIMIDES CLUSTERS ON SCAFFOLDING FOR PLURIVALENT PEPTIDE ASSEMBLIES
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
SI1625156T1 (sl) 2003-05-12 2013-02-28 Affymax, Inc. Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
JP4266028B2 (ja) 2003-05-12 2009-05-20 アフィーマックス・インコーポレイテッド エリスロポエチン受容体に結合する新規ペプチド
JP2007530440A (ja) 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
WO2004100997A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
EP1538164A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG RGD targeting moiety its production and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US20030099629A1 (en) * 1999-03-11 2003-05-29 Immunomedics, Inc. Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5009011440; ＯＢＲＩＳＴ　Ｒ: ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＯＰＨＡＲＭＡＣＯＬＯＧＹ Ｖ５　Ｎ４, 19830101, Ｐ３０７-３１４, ＥＬＭＳＦＯＲＤ *
JPN5009011441; ＯＢＲＩＳＴ　Ｒ: ＣＥＬＬＵＬＡＲ　ＩＭＭＵＮＯＬＯＧＹ Ｖ８１　Ｎ１, 19830101, Ｐ１６９-１７４, ＡＣＡＤＥＭＩＣ　ＰＲＥＳＳ *
JPN5009011442; ＨＥＴＬＡＮＤ　Ｇ: ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖ１１　Ｎ３, 19950101, Ｐ８５-９３, ＢＩＯＳＣＩＥＮＣＥ　ＥＤＩＰＲＩＮＴ　ＩＮＣ． *
JPN7013000053; Ｂｉｏｃｈｅｍｉｃａｌ　ａｎｄ　ｂｉｏｐｈｙｓｉｃａｌ　ｒｅｓｅａｒｃｈ　ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．１５５, 1988, ｐ．１１３９-１１４４ *
JPN7013000054; Ｅｕｒ．Ｊ．Ｉｍｍｕｎｏｌ． Ｖｏｌ．３５, 2005, ｐ．２４８６-２４９５ *
JPN7013000055; ＦＡＳＥＢ　Ｊｏｕｒｎａｌ Ｖｏｌ．１９, 2005, ｐ．１９７８-１９８５ *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513358A (ja) * 2012-03-22 2015-05-11 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ 金結合性及びｅｇｆｒ受容体親和性を有するペプチド、並びに金ナノ構造に結合したペプチド
JP2019523782A (ja) * 2016-05-24 2019-08-29 シンタプ セラピューティクス ゲーエムベーハー 合成化合物
US11318208B2 (en) 2016-05-24 2022-05-03 Syntab Therapeutics Gmbh Synthetic compound
JP7449091B2 (ja) 2016-05-24 2024-03-13 シンタプ セラピューティクス ゲーエムベーハー 合成化合物
JP2020523413A (ja) * 2017-06-16 2020-08-06 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
JP7073487B2 (ja) 2017-06-16 2022-05-23 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
JP2022106976A (ja) * 2017-06-16 2022-07-20 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
JP2022106970A (ja) * 2017-06-16 2022-07-20 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
JP2022106975A (ja) * 2017-06-16 2022-07-20 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
JP7467526B2 (ja) 2017-06-16 2024-04-15 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
JP2024054197A (ja) * 2017-06-16 2024-04-16 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
JP7553504B2 (ja) 2017-06-16 2024-09-18 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体

Also Published As

Publication number Publication date
EP3669894A2 (en) 2020-06-24
CN101528263A (zh) 2009-09-09
EP2275142A2 (en) 2011-01-19
US20100233161A1 (en) 2010-09-16
JP2017002039A (ja) 2017-01-05
JP2014166186A (ja) 2014-09-11
EP2035041B1 (en) 2020-01-08
WO2008000517A2 (en) 2008-01-03
WO2008000517A3 (en) 2009-04-02
US8470963B2 (en) 2013-06-25
EP2275142A3 (en) 2011-05-11
EP3669894A3 (en) 2020-08-26
EP2035041A2 (en) 2009-03-18
CN101528263B (zh) 2013-01-23

Similar Documents

Publication Publication Date Title
CN101528263B (zh) 用于癌症的先天性免疫方法的缀合物
JP4718183B2 (ja) 免疫反応を調節するためのモジュラー抗原トランスポーター分子（ｍａｔ分子）、関連する構築物、方法、および使用
US20040014652A1 (en) Tumor activated prodrug compounds and methods of making and using the same
US10202421B2 (en) Tumor-targeting compounds
WO2001091798A2 (en) Tumor activated prodrug compounds
JP2001512739A (ja) 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途
KR20120125455A (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
KR102704977B1 (ko) 신규 뉴클레오린-결합 펩타이드 및 이의 용도
JP7449091B2 (ja) 合成化合物
KR20260006040A (ko) 면역조정 특성을 갖는 펩티드
PL207174B1 (pl) Glikopeptydy, sposób ich wytwarzania, koniugaty glikopeptydów, płytki do diagnozy, metody diagnostyczne i zestaw do diagnozowania stwardnienia rozsianego
JP2003534387A (ja) 腫瘍活性化プロドラッグ化合物、並びにこれらの製造方法及び使用方法
Uray et al. Synthesis and receptor binding of IgG1 peptides derived from the IgG Fc region
EP4332219B1 (en) Cargo molecule tranduction domain rmad1, variant thereof, recombinant cargo molecule, and method for tranducing cargo molecule using same
WO2010111910A1 (zh) 一种合成肽及其应用
CA2362464A1 (en) A synthetic peptide disturbing intracellular signaling
WO2025262329A1 (en) Synthetic molecules comprising tlr2 ligands
EP4230223A1 (en) Composition
CN117043329A (zh) 货物分子转导结构域rmad1、其的变体、重组货物分子以及利用其的货物分子转导方法
Smyrniotou et al. 2-Oxoamides based on dipeptides and pseudodipeptides as inhibitors of Ca2+-independent phospholipase A2
HK40006607A (en) Synthetic compound

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140107